Koios Pharmaceuticals files challenge to high-cost drug’s patent
California, USA-based Koios Pharmaceuticals announced that it has filed a challenge to the validity of US Patent 8,644,231, the sole Orange-Book listed patent protecting Rasuvo - a methotrexate autoinjector product marketed by the US subsidiary of privately-held German firm medac GmbH - from generic competition.
Koios further announced that it has entered into a confidential development and commercialization partnership with a leading developer of sterile injectable pharmaceutical products to introduce a generic equivalent to Rasuvo.
Rasuvo is approved in the USA for the treatment of inflammatory autoimmune diseases including rheumatoid arthritis in adults and polyarticular juvenile idiopathic arthritis in children.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze